bell
The current prices are delayed by 15 mins, login to check live prices.
Concord Biotech Ltd share price logo

Concord Biotech Ltd

(CONCORDBIO)

₹2019.31.41%

as on 04:01PM, 22 Nov 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Concord Biotech Ltd Analyst Rating

based on 4 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 4 analysts offering long term price targets for Concord Biotech Ltd. An average target of ₹2041.25

Source: S&P Global Market Intelligence

Concord Biotech Ltd Share analysis

Concord Biotech Ltd price forecast by 4 analysts

Upside of2.51%

High

₹2208

Target

₹2041.25

Low

₹1720

Concord Biotech Ltd target price ₹2041.25, a slight upside of 2.51% compared to current price of ₹2019.3. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Concord Biotech Ltd Performance

  • Day's Low

    Day's High

    ₹1,959.15
    ₹2,045
  • 52 Week's Low

    52 Week's High

    ₹1,205.45
    ₹2,664
1 Month Return+ 8.27 %
3 Month Return+ 24.56 %
1 Year Return+ 57.82 %
Previous Close₹1,991.20
Open₹1,992.15
Volume74.97K
Upper Circuit-
Lower Circuit-
Market Cap₹20,831.18Cr

Concord Biotech Ltd Key Statistics

P/E Ratio63.54
PEG Ratio28.36
Market Cap₹20,831.18 Cr
P/B Ratio10.44
EPS29.45
Dividend Yield0.57
SectorPharmaceuticals
ROE21.63

Concord Biotech Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹20,831.18 Cr22.24%0.50₹308 Cr₹1,016 Cr
BUY₹14,767.55 Cr100.04%0.50₹461 Cr₹1,694 Cr
NA₹315.78 Cr42.44%0.74NANA
NA₹152.88 Cr5.23%0.60NANA
BUY₹13,205.46 Cr63.28%0.63₹405 Cr₹4,506 Cr

About Concord Biotech Ltd

Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad Gujarat as a Private Limited Company dated November 23 1984 issued by the Registrar of Companies. Thereafter name of the Company was changed to Concord Biotech Limited dated February 16 2001 which became a Public Company and a fresh Certificate of Incorporation dated November 7 2001 was issued by the RoC.The Company is an Indiabased biopharma and one of the leading global developers and manufacturers of select fermentationbased APIs across immunosuppressants and oncology in terms of market share based on volume in supplying to over 70 countries including regulated markets such as the United States Europe and Japan and India. Presently it is engaged in research and development manufacturing marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi and formulations facility at Valthera in Gujarat.In 2000 the Company was acquired by the Promoter Mr. Sudhir Vaid. In 2016 the Company launched formulation business in India as well as emerging markets including Nepal Mexico Indonesia Thailand Ecuador Kenya Singapore and Paraguay and have further expanded to the United States. It established a facility at Valthera Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019 the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020 Mycophenolate Sodium Tablets got launched in the US market.A second API manufacturing facility at Limbasi was launched which commenced operations in July 2021. As of March 31 2022 the Company had 6 fermentationbased immunosuppressant APIs including tacrolimus mycophenolate mofetil mycophenolate sodium cyclosporine sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat India comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera which were commercialized in 2000 2021 and 2016 respectively. Their total annual installed fermentation capacity for APIs was 1250 m3 as of March 31 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31 2022 the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units with an average dosage capability of 0.17 million tablets 0.36 million capsules and 646.46 bottles of dry syrup per shift which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20925652 Equity Shares through Offer for Sale..

Share Price: ₹2019.30 per share as on 22 Nov, 2024 04:01 PM
Market Capitalisation: ₹20,831.18Cr as of today
Revenue: ₹310.18Cr as on September 2024 (Q3 24)
Net Profit: ₹95.74Cr as on September 2024 (Q3 24)
Listing date: 18 Aug, 2023
Chairperson Name: SUDHIR JAIRAM VAID
OrganisationConcord Biotech Ltd
HeadquartersAhmedabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Concord Biotech Ltd

  • Concord Biotech Maintains Growth Outlook Amid Stock Decline - 20 Nov, 2024

    Concord Biotech Ltd has seen a 6.45% decline over 51 days but reiterated its high-teen revenue growth guidance. The API segment is expected to grow from H2FY25, with top products contributing significantly to revenue. Antique Stock Broking maintains a Buy rating with a revised target price of Rs 2,187.

  • Concord Biotech Reports Strong Q3 2024 Financials - 13 Nov, 2024

    Concord Biotech's standalone net sales for September 2024 reached Rs 310.18 crore, up 18.23% YoY. Net profit rose 16.81% to Rs 98.70 crore, with EBITDA increasing by 15.22%. EPS improved to Rs 9.43 from Rs 8.08 in the previous year.

  • Concord Biotech Reports Strong Q2 FY25 Earnings - 11 Nov, 2024

    Concord Biotech's Q2 FY25 results show an 18.2% YoY revenue increase to ₹310.18 crore and an 18% YoY rise in PAT to ₹95.74 crore, reflecting robust growth.

Insights on Concord Biotech Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 7.11% to 8.10% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 59.59 Cr → 95.74 Cr (in ₹), with an average increase of 37.8% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 227.46 Cr → 320.21 Cr (in ₹), with an average increase of 29.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, CONCORDBIO stock has moved up by 4.0%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 44.08% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 5.26% to 4.97% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 38.41% to 37.93% in Sep 2024 quarter

Concord Biotech Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹262.35Cr (-)₹240.80Cr (↓8.21%)₹318.97Cr (↑32.46%)₹215.80Cr (↓32.34%)₹310.18Cr (↑43.73%)
Net Income₹81.02Cr (-)₹77.57Cr (↓4.26%)₹95.02Cr (↑22.50%)₹59.59Cr (↓37.29%)₹95.74Cr (↑60.66%)
Net Profit Margin30.88% (-)32.21% (↑4.31%)29.79% (↓7.51%)27.61% (↓7.32%)30.87% (↑11.81%)
Value in ₹ crore
Details2021202220232024
Total Assets₹1,183.44Cr (-)₹1,315.40Cr (↑11.15%)₹1,516.84Cr (↑15.31%)₹1,701.77Cr (↑12.19%)
Total Liabilities₹183.77Cr (-)₹208.24Cr (↑13.32%)₹224.86Cr (↑7.98%)₹176.52Cr (↓21.50%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹154.94Cr (-)₹166.81Cr (↑7.66%)₹207.47Cr (↑24.38%)₹246.00Cr (↑18.57%)₹265.47Cr (↑7.91%)

Index Inclusions

S&P BSE 250 SmallCap

₹6,797.77

0.93 (62.78%)

Nifty 500

₹22,225.55

1.85 (404.7%)

Nifty MidSmallcap 400

₹19,196.45

1.09 (206.7%)

BSE Healthcare

₹42,969.55

1.23 (522.48%)

Nifty Smallcap 250

₹16,912.30

0.98 (164.45%)

BSE 500

₹35,009.77

1.89 (648.36%)

S&P BSE 400 MidSmallCap

₹11,760.86

1.18 (137.44%)

BSE Small-Cap

₹52,612.93

0.9 (471.78%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Concord Biotech Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
44.08%
0.00
Foreign Institutions
8.1%
13.93
Mutual Funds
4.97%
-5.54
Retail Investors
37.93%
-1.23
Others
4.92%
-4.37

Concord Biotech Ltd Key Indicators

Details20202021202220232024
Return On Equity %20.8626.5916.9519.8521.63
Details2021202220232024
Return On Assets %19.8913.315.8318.1
Details2024
Book Value Per Share (₹)145.93
Details2024
Earning Per Share (₹)29.45

Concord Biotech Ltd Valuation

Concord Biotech Ltd in the last 5 years

  • Overview

  • Trends

Lowest (36.27x)

October 4, 2023

Industry (54.82x)

November 21, 2024

Today (63.54x)

November 21, 2024

Highest (86.91x)

September 20, 2024

LowHigh

Concord Biotech Ltd Earnings and Dividends

  • Concord Biotech Ltd Earnings Results

    Concord Biotech Ltd’s net profit jumped 18.17% since last year same period to ₹95.74Cr in the Q2 2024-2025. On a quarterly growth basis, Concord Biotech Ltd has generated 60.66% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Concord Biotech Ltd Dividends May,2024

    In the quarter ending March 2024, Concord Biotech Ltd has declared dividend of ₹8.75 - translating a dividend yield of 0.43%.

    Read More about Dividends

Concord Biotech Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Concord Biotech Ltd is currently in a Bullish trading position according to technical analysis indicators.

FAQs on Concord Biotech Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Concord Biotech Ltd shares.

Concord Biotech Ltd (CONCORDBIO) share price today is ₹2019.3

Concord Biotech Ltd is listed on NSE

Concord Biotech Ltd is listed on BSE

  • Today’s highest price of Concord Biotech Ltd is ₹2045.
  • Today’s lowest price of Concord Biotech Ltd is ₹1959.15.

PE Ratio of Concord Biotech Ltd is 63.54

PE ratio = Concord Biotech Ltd Market price per share / Concord Biotech Ltd Earnings per share

Today’s traded volume of Concord Biotech Ltd(CONCORDBIO) is 74.97K.

Today’s market capitalisation of Concord Biotech Ltd(CONCORDBIO) is ₹20831.18Cr.

Concord Biotech Ltd(CONCORDBIOPrice
52 Week High
₹2664
52 Week Low
₹1205.45

Concord Biotech Ltd(CONCORDBIO) share price is ₹2019.3. It is down -24.20% from its 52 Week High price of ₹2664

Concord Biotech Ltd(CONCORDBIO) share price is ₹2019.3. It is up 67.51% from its 52 Week Low price of ₹1205.45

Concord Biotech Ltd(CONCORDBIOReturns
1 Day Returns
28.1%
1 Month Returns
8.27%
3 Month Returns
24.56%
1 Year Returns
57.82%